EDAP TMS (EDAP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EDAP TMS has announced significant findings from the HIFI study, highlighting the effectiveness of its Focal One robotic HIFU technology in treating localized prostate cancer. The study, published in European Urology, shows Focal One as a less invasive alternative to surgery with better outcomes in urinary continence and erectile function. These results could increase the adoption of Focal One as a primary treatment option, offering a promising advancement in prostate cancer care.
For further insights into EDAP stock, check out TipRanks’ Stock Analysis page.